| S8723 |
ABBV-744 |
ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers. |
Selective |
|
| S3573 |
Trotabresib |
Trotabresib(BMS-986378,CC-90010) is a reversible, orally active and central nervous system-penetrant inhibitor of bromodomain and extra-terminal (BET) proteins. CC-90010 is applied in the study for advanced solid tumors. |
Selective |
|
| S6397 |
Thalidomide-NH-C4-NH-Boc |
Thalidomide-NH-C4-NH-Boc is a novel, potent, and selective class of Bromodomain-containing protein 4 (BRD4) and Bromodomain-containing protein 2 (BRD2) degrader for the development of therapeutics to treat cancers. |
Selective |
|
| S9685 |
GSK620 |
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics. |
Selective |
|
| S8961 |
Alobresib (GS-5829) |
Alobresib (GS-5829) is a novel BET inhibitor that represents a highly effective therapeutics agent against recurrent/chemotherapy-resistant USC-overexpressing c-Myc. Alobresib (GS-5829) inhibits CLL cell proliferation and induces leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC. Alobresib (GS-5829) also inhibits NF-κB signaling. |
Selective |
|
| S8753 |
INCB054329 |
INCB054329 is a structurally distinct bromodomain and extraterminal domain (BET) inhibitor with IC50 values of 44 nM, 5 nM, 9 nM, 1 nM, 28 nM, 3 nM, 119 nM and 63 nM for BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2, respectively. |
Selective |
BRD2-BD1, IC50: 44 nM; BRD2-BD2, IC50: 5 nM; BRD3-BD1, IC50: 9 nM; BRD3-BD2, IC50: 1 nM; BRD4-BD1, IC50: 28 nM; BRD4-BD2, IC50: 3 nM; BRDT-BD1, IC50: 119 nM; BRDT-BD2, IC50: 63 nM |
| S8739 |
PLX51107 |
PLX51107 is as a novel BET inhibitor with modest preference for bromodomain-1 (BD1) versus bromodomain-2 (BD2) within each BET protein (Kd = 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1 and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively. Among non-BET proteins, PLX51107 shows significant interactions only with the bromodomains of CBP and EP300 (p300) (Kd in the 100 nM range). |
Selective |
BRD2 BD1, Kd: 1.6 nM; BRD2 BD2, Kd: 5.9 nM; BRD3 BD1, Kd: 2.1 nM; BRD3 BD2, Kd: 6.2 nM; BRD4 BD1, Kd: 1.7 nM; BRD4 BD2, Kd: 6.1 nM; BRDT BD1, Kd: 5 nM; BRDT BD2, Kd: 120 nM |
| S8574 |
BRD4 Inhibitor-10 |
BRD4 Inhibitor-10(BI 894999) is a potent BRD4-BD1 inhibitor with an IC50 of 8 nM. |
Selective |
BRD4-BD1, IC50: 5 nM; BRD4-BD2, IC50: 41 nM |
| S8344 |
AZD-5153 6-hydroxy-2-naphthoic acid |
AZD-5153 6-hydroxy-2-naphthoic acid (HNT salt) is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor with pKi of 8.3 for BRD4. AZD-5153 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes. NSD3, via H3K36me2, acts as an epigenetic deregulator to facilitate the expression of oncogenesis-promoting genes. |
Selective |
FL-BRD4, IC50: 5 nM |
| S8889 |
MZ-1 |
MZ-1 is a PROTAC degrader of bromodomain-containing protein 4 (BRD4). MZ-1 binds to the Brd bromodomain with Kd of 62 nM, 60 nM, 21 nM, 13 nM, 39 nM and 15 nM for Brd2BD1, Brd2BD2, Brd3BD1, Brd3BD2, Brd4BD1 and Brd4BD2. |
Selective |
Brd2(BD1), Kd: 62 nM; Brd2(BD2), Kd: 60 nM; Brd3(BD1), Kd: 21 nM; Brd3(BD2), Kd: 13 nM; Brd4(BD1), Kd: 39 nM; Brd4(BD2), Kd: 15 nM |
| S8762 |
dBET6 |
dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis. |
Selective |
BRD4, IC50: 14 nM |
| S7360 |
Birabresib (OTX015) |
Birabresib (OTX015, MK 8628) is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4 in cell-free assays. Birabresib inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes. |
Selective |
BRDs, EC50: 10-19 nM |
| S8179 |
BI-7273 |
BI-7273 is a potent, selective, and cell-permeable BRD9 BD inhibitor with IC50s of 19 nM and 117 nM for BRD9 and BRD7 respectively in alpha assay. |
Selective |
BRD9, IC50: 19 nM; BRD7, IC50: 117 nM |
| S8296 |
dBET1 |
dBET1 is a CRBN-based BET degrader with an IC50 of 20 nM, showing highly selectivity. Out of 7,429 proteins, only the expression of the oncoproteins MYC and PIM1, as well as BRD2, BRD3 and BRD4 are significantly downregulated by dBET1 treatment. |
Selective |
BRD4, IC50: 20 nM |
| S7620 |
GSK1324726A (I-BET726) |
GSK1324726A (I-BET726) is a highly selective inhibitor of BET family proteins with IC50 of 41 nM, 31 nM, and 22 nM for BRD2, BRD3, and BRD4, respectively.
|
Selective |
BRD2, IC50: 41 nM; BRD3, IC50: 31 nM; BRD4, IC50: 22 nM |
| S8763 |
ZL0420 |
ZL0420 is a potent and selective BRD4 inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2 respectively and good selectivity over that of the related BRD2 homolog. |
Selective |
BRD4 BD1, IC50: 27 nM; BRD4 BD2, IC50: 32 nM |
| S8297 |
ARV-825 |
ARV-825 is a BRD4 Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC. |
Selective |
BRD4 BD1, Kd: 90 nM; BRD4 BD2, Kd: 28 nM |
| S7110 |
(+)-JQ1 |
(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy. (+)-JQ1 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes. |
Selective |
BRD4 (1), IC50: 77 nM; BRD4 (2), IC50: 33 nM |
| S7189 |
Molibresib (I-BET-762) |
Molibresib (I-BET-762, GSK525762, GSK525762A) is an inhibitor for BET proteins with IC50 of ~35 nM in a cell-free assay, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins. |
Selective |
BET proteins, IC50: 35 nM |
| S1109 |
BI 2536 |
BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2. |
Selective |
BRD4, Kd: 37 nM |
| S7304 |
CPI-203 |
CPI-203 is a potent BET bromodomain inhibitor with IC50 of 37 nM for BRD4.
|
Selective |
BRD4, IC50: 37 nM |
| S7853 |
Pelabresib (CPI-0610) |
Pelabresib (CPI-0610) is a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor with an IC50 of 39 nM for BRD4-BD1 in TR-FRET assay and currently undergoing human clinical trials for hematological malignancies. CPI-0610 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes. |
Selective |
BRD4-BD1, IC50: 39 nM |
| S9683 |
GSK778 |
GSK778 (iBET-BD1) is a strong BD1 bromodomain inhibitor of the BET proteins, with IC50 value of 75 nM for BRD2 BD1, 41 nM for BRD3 BD1, 41 nM for BRD4 BD1, and 143 nM for BRDT BD1. |
Selective |
BRD2-BD1, IC50: 75nM; BRD3-BD1, IC50: 41 nM; BRD4-BD1, IC50: 41 nM; BRDT-BD1, IC50: 143 nM |
| S7835 |
I-BRD9 |
I-BRD9 (GSK602) is a potent and selective BRD9 inhibitor with pIC50 of 7.3, while it displayed a pIC50 of 5.3 against BRD4. |
Selective |
BRD9, pIC50: 7.3; BRD4, pIC50: 5.3 |
| S0344 |
Y06036 |
Y06036 (Compound 6i) is a potent and selective inhibitor of BET with antitumor activity. Y06036 binds to the BRD4(1) bromodomain with Kd of 82 nM. |
Selective |
BRD4 (1), Kd: 82 nM |
| S7305 |
MS436 |
MS436 is a selective BET bromodomain inhibitor with Ki of <0.085 μM and 0.34 μM for BRD4 (1) and BRD4 (2), respectively.
|
Selective |
BRD4 (1), Ki: <0.085 μM; BRD4 (2), Ki: 0.34 μM |
| S1216 |
PFI-1 (PF-6405761) |
PFI-1 (PF-6405761) is a highly selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM and for BRD2 with IC50 of 98 nM in a cell-free assay. |
Selective |
BRD4, IC50: 0.22 μM; BRD2, IC50: 98 nM |
| S7525 |
XMD8-92 |
XMD8-92 is a potent and selective dual inhibitor of big map kinase (BMK1, ERK5) and bromodomain-containing proteins (BRDs, BET) with Kd of 80 nM and 170 nM for ERK5 and BRD4(1), respectively. |
Selective |
BRD4 (1), Kd: 170 nM |
| S8589 |
SF2523 |
SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively. |
Selective |
BRD4, IC50: 241 nM |
| S2780 |
I-BET151 (GSK1210151A) |
I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively. |
Selective |
BRD2, IC50: 0.5 μM; BRD3, IC50: 0.25 μM; BRD4, IC50: 0.79 μM |
| S1027 |
FL-411 |
FL-411 (BRD4-IN-1) is a potent and selective inhibitor of Bromodomain-containing protein 4 (BRD4) with IC50 of 0.43 μM for BRD4(1). FL-411 induces ATG5-dependent autophagy-associated cell death (ACD) by blocking BRD4-AMPK interaction. |
Selective |
BRD4(1), IC50: 0.43 μM |
| S7295 |
Apabetalone (RVX-208) |
Apabetalone (RVX-208, RVX-000222) is a potent BET bromodomain inhibitor with IC50 of 0.510 μM for BD2 in a cell-free assay, about 170-fold selectivity over BD1. Phase 2. |
Selective |
BD2, IC50: 0.51 μM |
| S8948 |
SRX3207 |
SRX3207 is an orally active dual inhibitor of Syk-PI3K with IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM for Syk, Zap70, BRD41, BRD42, PI3K alpha, PI3K delta, PI3K gamma, respectively. SRX3207 blocks tumor immunosuppression and increases anti-tumor immunity. |
Selective |
BRD41, IC50: 3070 nM; BRD42, IC50: 3070 nM |
| S8400 |
Mivebresib (ABBV-075) |
Mivebresib (ABBV-075) is a novel BET family bromodomain inhibitor. It binds bromodomains of BRD2/4/T with similar affinities (Ki of 1-2.2 nM) and highly selective for 18 bromodomain proteins tested (Kd > 1 μM; more than 600-fold selectivity vs. BRD4), but exhibits roughly 10-fold weaker potency towards BRD3 (Ki of 12.2 nM) and has moderate activity towards CREBBP (Kd = 87 μM; 54-fold selectivity vs. BRD4). Mivebresib(ABBV-075) efficiently triggers apoptosis in various tumor cell. |
Selective |
|
| S8785 |
A1874 |
A1874 is a much improved nutlin-based, BRD4-degrading PROTAC and is able to degrade its target protein by 98% with nanomolar potency. |
Selective |
|
| S8714 |
INCB057643 |
INCB057643 is a BET inhibitor that binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. |
Selective |
|
| S9691 |
BMS-986158 |
BMS-986158 is a potent inhibitor of BET with IC50s of 6.6 nM and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively. |
Selective |
|
| S8113 |
BI-9564 |
BI-9564 is a selective inhibitor of BRD9 and BRD7 bromodomains with the IC50 of 75 nM and 3.4 µM, respectively. |
Pan |
BRD9, Kd: 5.9 nM; BRD7, Kd: 73 nM |
| S9648 |
NEO2734 |
NEO2734 (EP31670) is a novel, orally active and selective dual inhibitor of p300/CBP and BET bromodomain with IC50 of both <30 nM. |
Pan |
BET, IC50: <30 nM |
| S7233 |
Bromosporine |
Bromosporine is a broad spectrum inhibitor for bromodomains with IC50 of 0.41 μM, 0.29 μM, 0.122 μM and 0.017 μM for BRD2, BRD4, BRD9 and CECR2, respectively. |
Pan |
BRD2, IC50: 0.41 μM; BRD4, IC50: 0.29 μM; BRD9, IC50: 0.122 μM |
| S8665 |
GNE-781 |
GNE-781 (compound 19) is an orally active, highly potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP) with IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50 of 6.2 nM and 5100 nM, respectively. GNE-781 exhibits antitumor activity. |
Pan |
BRD4(1), IC50: 5100 nM |
